title: [Biological and immunogenic characteristics of Chlamydia trachomatis strain MT-2A (serovar D) and its use for development of experimental inactivated vaccine].
abstract: Biological characteristics of C. trachomatis author's strain MT-2A (serovar D) is presented. Stages of development on its basis the experimental formalin-inactivated vaccine against Chlamydia were described. Humoral and cellular immune response to the vaccine administered on 3-dose immunization schedule in conjunction with polyoxidonium as adjuvant was studied. Significant immunological efficacy of the vaccine was shown. T- and B-cell immune responses were characterized. Titer of IgG antibodies against Chlamydia in blood serum after 3rd dose of the vaccine was 10,880+/-1,817.76. Assessment of T-cell response showed that reaction of delayed hypersensitivity with formation of granuloma presented in 60% of animals. Proportion of immunoblasts in reaction of blast-transformation was 29.3+/-2.8%. Perspectives of further studies of the developed corpuscular vaccine against Chlamydia are discussed.
authors.forename: N N
authors.initials: NN
authors.lastname: Poleshchuk
authors.forename: L V
authors.initials: LV
authors.lastname: Rubanik
authors.forename: N N
authors.initials: NN
authors.lastname: Kapitulets
authors.forename: Z B
authors.initials: ZB
authors.lastname: Kvacheva
authors.forename: S A
authors.initials: SA
authors.lastname: Kostiuk
authors.forename: D A
authors.initials: DA
authors.lastname: Chernosheĭ
authors.forename: S P
authors.initials: SP
authors.lastname: Kapitulets
authors.forename: L P
authors.initials: LP
authors.lastname: Titov
mesh_terms: D000818:Animals; D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D001425:Bacterial Outer Membrane Proteins / Q000276:immunology; D001428:Bacterial Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*; D002478:Cells, Cultured; D002690:Chlamydia Infections / Q000276:immunology*; D002692:Chlamydia trachomatis / Q000276:immunology*; D004353:Drug Evaluation, Preclinical; D006099:Granuloma / Q000209:etiology; D006968:Hypersensitivity, Delayed / Q000209:etiology; D007115:Immunization Schedule; D007279:Injections, Subcutaneous; D008213:Lymphocyte Activation; D051379:Mice; D011817:Rabbits; D013154:Spleen / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology; D015164:Vaccines, Inactivated / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology
chemical_list: D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D001425:Bacterial Outer Membrane Proteins; D001428:Bacterial Vaccines; D015164:Vaccines, Inactivated